The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation

Biomaterials

Volumn 34, Issue 31, 2013, Pages 7653-7661

  Salbach Hirsch, Juliane ^a   Kraemer, Julia ^b   Rauner, Martina ^a   Samsonov, Sergey A ^b   Pisabarro, M Teresa ^b   Moeller, Stephanie ^c   Schnabelrauch, Matthias ^c   Scharnweber, Dieter ^b,d   Hofbauer, Lorenz C ^a,d   Hintze, Vera ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c BIOMATERIALS DEPARTMENT   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Hyaluronic acid hyaluronan (HA) sulfate; Osteoclast (OC); Osteoprotegerin (OPG); Receptor activator of NF B ligand (RANKL); Surface plasmon resonance (SPR)

Indexed keywords

BIOMATERIAL COATINGS; EXTRACELLULAR MATRICES; GLYCOSAMINOGLYCANS; MOLECULAR MODELING TECHNIQUES; OSTEOCLAST (OC); OSTEOPROTEGERIN; RECEPTOR ACTIVATOR; SULFATED HYALURONAN;

BINDING SITES; BIOLOGICAL MATERIALS; BIOMATERIALS; BONE; LIGANDS; PLASMONS; SULFUR COMPOUNDS; SURFACE PLASMON RESONANCE;

HYALURONIC ACID;

GLYCOSAMINOGLYCAN; HYALURONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SULFATE;

ANIMAL CELL; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; BONE REGENERATION; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MOLECULAR MODEL; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SULFATION; SURFACE PLASMON RESONANCE;

EID: 84880931573     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.053     Document Type: Article

References (32)

1. Mathieu L.M., Mueller T.L., Bourban P.-E.E., Pioletti D.P., Muller R., Manson J.A., et al. Architecture and properties of anisotropic polymer composite scaffolds for bone tissue engineering. Biomaterials 2006, 27:905-916.
2. Hench L.L. Biomaterials: a forecast for the future. Biomaterials 1998, 19:1419-1423.
3. Salbach J., Kliemt S., Rauner M., Rachner T.D., Goettsch C., Kalkhof S., et al. The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. Biomaterials 2012, 33:8418-8429.
4. Pichert A., Samsonov S.A., Theisgen S., Thomas L., Baumann L., Schiller J., et al. Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Glycobiology 2012, 22:134-145.
5. Prince C.W., Navia J.M. Glycosaminoglycan alterations in rat bone due to growth and fluorosis. JNutr 1983, 113:1576-1582.
6. Salbach J., Rachner T.D., Rauner M., Hempel U., Anderegg U., Franz S., et al. Regenerative potential of glycosaminoglycans for skin and bone. JMol Med 2012, 90:625-635.
7. Ariyoshi W., Takahashi T., Kanno T., Ichimiya H., Shinmyouzu K., Takano H., et al. Heparin inhibits osteoclastic differentiation and function. JCell Biol 2008, 103:1707-1717.
8. Shinmyouzu K., Takahashi T., Ariyoshi W., Ichimiya H., Kanzaki S., Nishihara T. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand. Biochem Bioph Res Co 2007, 354:447-452.
9. Hintze V., Miron A., Moeller S., Schnabelrauch M., Wiesmann H.-P., Worch H., et al. Sulfated hyaluronan and chondroitin sulfate derivatives interact differently with human transforming growth factor-β1 (TGF-β1). Acta Biomaterialia 2012, 8:2144-2152.
10. Hintze V., Moeller S., Schnabelrauch M., Bierbaum S., Viola M., Worch H., et al. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules 2009, 10:3290-3297.
11. Kunze R., Rösler M., Möller S., Schnabelrauch M., Riemer T., Hempel U., et al. Sulfated hyaluronan derivatives reduce the proliferation rate of primary rat calvarial osteoblasts. Glycoconj J 2010, 27:151-158.
12. Satoh A., Kojima K., Koyama T., Ogawa H., Matsumoto I. Immobilization of saccharides and peptides on 96-well microtiter plates coated with methyl vinyl ether-maleic anhydride copolymer. Anal Biochem 1998, 260:96-102.
13. Luan X., Lu Q., Jiang Y., Zhang S., Wang Q., Yuan H., et al. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. JImmunol 2012, 189:245-252.
14. Morris G.M., Goodsell D.S., Huey R., Olson A.J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. JComput Aid Mol Des 1996, 10:293-304.
15. Vives V., Laurin M., Cres G., Larrousse P., Morichaud Z., Noel D., et al. The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts. JBone Miner Res 2011, 26:1099-1110.
16. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675.
17. Soares-Schanoski A., Gómez-Piña V., Del Fresno C., Rodríguez-Rojas A., García F., Glaría A., et al. 6-Methylprednisolone down-regulates IRAK-M in human and murine osteoclasts and boosts bone-resorbing activity: a putative mechanism for corticoid-induced osteoporosis. JLeukoc Biol 2007, 82:700-709.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
19. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
20. Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008, 473:139-146.
21. Griffith G.C., Nichols G., Asher J.D., Flanagan B. Heparin osteoporosis. JAMA 1965, 193:91-94.
22. Jaffe M.D., Willis P.W. Multiple fractures associated with long-term sodium heparin therapy. JAMA 1965, 193:158-160.
23. Miller W.E., DeWolfe V.G. Osteoporosis resulting from heparin therapy. Report of a case. Cleveland Clinic Q 1966, 33:31-34.
24. Goldhaber P. Heparin enhancement of factors stimulating bone resorption in tissue culture. Sci (N.Y.) 1965, 147:407-408.
25. Fuller K., Chambers T.J., Gallagher a C. Heparin augments osteoclast resorption-stimulating activity in serum. JCell Physiol 1991, 147:208-214.
26. Velasco C.R., Baud'huin M., Sinquin C., Maillasson M., Heymann D., Colliec-Jouault S., et al. Effects of a sulfated exopolysaccharide produced by Alteromonas infernus on bone biology. Glycobiology 2011, 21:781-795.
27. Irie A., Takami M., Kubo H., Sekino-Suzuki N., Kasahara K., Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007, 41:165-174.
28. Théoleyre S., Kwan Tat S., Vusio P., Blanchard F., Gallagher J., Ricard-Blum S., et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006, 347:460-467.
29. Lamoureux F., Picarda G., Garrigue-Antar L., Baud'huin M., Trichet V., Vidal A., et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res 2009, 69:526-536.
30. Li Z., Hou W.S., Escalante-Torres C.R., Gelb B.D., Bromme D. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. JBiol Chem 2002, 277:28669-28676.
31. Hempel U., Hintze V., Möller S., Schnabelrauch M., Scharnweber D., Dieter P. Artificial extracellular matrices composed of collagen I and sulfated hyaluronan with adsorbed transforming growth factor β1 promote collagen synthesis of human mesenchymal stromal cells. Acta Biomater 2012, 8:659-666.
32. Van der Smissen A., Samsonov S.A., Hintze V., Scharnweber D., Moeller S., Schnabelrauch M., et al. Artificial extracellular matrix composed of collagen I and high-sulfated hyaluronan interferes with TGFβ1 signaling and prevents TGFβ1 induced myofibroblast differentiation. Acta Biomater 2013, [Epub ahead of print].